Publicaciones Científicas

Estudios preclínicos Estudios clínicos Estudios adicionales Inmunogenicidad "IN-VITRO"

ESTUDIOS PRECLÍNICOS:

RATAS SPRAGUE-DAWLEY:
Sun, W., Liu, Y., Amanat, F., González-Domínguez, I., McCroskery, S., Slamanig, S., Coughlan, L., Rosado, V., Lemus, N., Jangra, S., Rathnasinghe, R., Schotsaert, M., Martinez, J. L., Sano, K., Mena, I., Innis, B. L., Wirachwong, P., Thai, D. H., Oliveira, R. D. N., Hjorth, R., Raghunandan, R., Krammer, F., García-Sastre, A., Palese, P. (2021). A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. Nature Communications, 12(1), 1–14. https://doi.org/10.1038/s41467-021-26499-y

RATONES:
Sun, W., Liu, Y., Amanat, F., González-Domínguez, I., McCroskery, S., Slamanig, S., Coughlan, L., Rosado, V., Lemus, N., Jangra, S., Rathnasinghe, R., Schotsaert, M., Martinez, J. L., Sano, K., Mena, I., Innis, B. L., Wirachwong, P., Thai, D. H., Oliveira, R. D. N., Hjorth, R., Raghunandan, R., Krammer, F., García-Sastre, A., Palese, P. (2021). A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. Nature Communications, 12(1), 1–14. https://www.nature.com/articles/s41467-021-26499-y

CERDOS:
Lara-Puente, J. H., Carreño, J. M., Sun, W., Suárez-Martínez, A., Ramírez-Martínez, L., Quezada-Monroy, F., Paz-De la Rosa, G., Vigueras-Moreno, R., Singh, G., Rojas-Martínez, O., Chagoya-Cortés, H. E., Sarfati-Mizrahi, D., Soto-Priante, E., López-Macías, C., Krammer, F., Castro-Peralta, F., Palese, P., García-Sastre, A., & Lozano-Dubernard, B. (2021). Safety and immunogenicity of a Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate, AVX/COVID-12-HEXAPRO (Patria), in pigs. mBio, 12(5). https://journals.asm.org/doi/full/10.1128/mbio.01908-21

ESTUDIOS CLÍNICOS:

FASE I:
Ponce-de-León, S., Torres, M., Soto-Ramírez, L. E., Calva, J. J., Santillán-Doherty, P., Carranza-Salazar, D. E., Carreño, J. M., Carranza, C., Juárez, E., Carreto-Binaghi, L. E., Ramírez-Martínez, L., Paz De la Rosa, G., Vigueras-Moreno, R., Ortiz-Stern, A., López-Vidal, Y., Macías, A. E., Torres-Flores, J., Rojas-Martínez, O., Suárez-Martínez, A., Peralta-Sánchez, G., Kawabata, H., Gonzáles Domínguez, I., Martínez-Guevara, J., Sun, W., Lozano-Dubernard, B. (2023). Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico. Npj Vaccines, 8(1), 1–14. https://www.nature.com/articles/s41541-023-00662-6

FASE 2R:
(Preprint) López-Macías, C., Torres, M., Armenta-Copca, B., Wacher, N., Castro-Castrezana, L., Colli-Domínguez, A. A., Rivera-Hernández, T., Torres-Flores, A., Ramírez-Martínez, L., Paz-De la Rosa, G., Rojas-Martínez, O., Suárez-Martínez, A., Peralta-Sánchez, G., Carranza, C., Juárez, E., Zamudio-Meza, H., Carreto-Binaghi, L. E., Viettri, M., Romero-Rodríguez, D., Palencia, A., Reyna-Rosas, E., Márquez-García, J., Sarfati-Mizrahi, D., Sun, W., Chagoya-Cortés, H., Castro-Peralta, F., Palese, P., Krammer, F., Garcías-Sastre, A., Lozano-Dubernard, B. (2024). A phase II study integrating a single-blind safety phase with a double-blind, placebo-controlled randomized phase, assessing single-dose intramuscular or intranasal administration to evaluate the safety and immunogenicity of the recombinant vaccine against COVID-19 (AVX/COVID-12 “Patria”) based on an active Newcastle disease viral vector as a heterologous booster in subjects with evidence of previous immunity to SARS-CoV-2.. En bioRxiv (p. 2024.02.11.24302594). https://www.medrxiv.org/content/10.1101/2024.02.11.24302594v1

FASE 2/3:
(Preprint) López-Macías, C., Torres, M., Armenta-Copca, B., Wacher, N. H., Galindo-Fraga, A., Castro-Castrezana, L., Colli-Domínguez, A. A., Cervantes-Trujano, E., Rucker-Joerg, I. E., Lozano-Patiño, F., Rivera-Alcocer, J. J., Simón-Campos, A., Sánchez-Campos, E. A., Aguirre-Rivero, R., Muñiz-Carvajal, A. J., Carpio-Orantes, L. del, Márquez-Díaz, F., Rivera-Hernández, T., Torres-Flores, A., Ramírez-Martínez, L., Paz-De la Rosa, G., Rojas-Martínez, O., Suárez-Martínez, A., Peralta-Sánchez, G., Carranza, C., Juárez, E., Zamudio-Meza, H., Carreto-Binagh, L., Mercedes, V., Romero-Rodríguez, D., Palencia, A., Sarfati-Mizrahi, D., Sun, W., Chagoya-Corés,H., Castro-Peralta, F., Palese, P., Krammer, F., García-Sastre, A., Lozano-Dubernard, B. (2024). Phase II/III double-blind study evaluating safety and immunogenicity of a single intramuscular booster dose of the recombinant SARS-CoV-2 vaccine “Patria” (AVX/COVID-12) using an active Newcastle disease viral vector (NDV) during the omicron outbreak in healthy adults with elevated baseline antibody titers from prior COVID-19 and/or SARS-CoV-2 vaccination. En bioRxiv (p. 2024.02.11.24302530). https://www.medrxiv.org/content/10.1101/2024.02.11.24302530v1

ESTUDIOS ADICIONALES (POR MONTE SINAÍ):

Tcheou, J., Raskin, A., Singh, G., Kawabata, H., Bielak, D., Sun, W., González-Domínguez, I., Sather, D. N., García-Sastre, A., Palese, P., Krammer, F., & Carreño, J. M. (2021). Safety and immunogenicity analysis of a Newcastle disease virus (NDV-HXP-S) expressing the spike protein of SARS-CoV-2 in Sprague Dawley rats. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.791764

ESTUDIO ADICIONAL DE INMUNOGENICIDAD "IN-VITRO":

(Preprint) Torres-Flores, A., Ontiveros-Padilla, L. A., Madera-Sandoval, R. L., Tepale-Segura, A., Gajón-Martínez, J., Rivera-Hernández, T., Ferat-Osorio, E. A., Cérbulo-Vázquez, A., Arriaga-Pizano, L. A., Bonifaz, L., Paz-De la Rosa, G., Rojas-Martínez, O., Suárez-Martínez, A., Peralta-Sánchez, G., Sarfati-Mizrahi, D., Sun, W., Chagoya-Cortés, H. E., Palese, P., Krammer, F., López-Macías, C. (2024). Newcastle Disease virus vector-based SARS-CoV-2 vaccine candidate AVX/COVID-12 activates T cells and is recognized by antibodies from COVID-19 patients and vaccinated. En bioRxiv. https://www.biorxiv.org/content/10.1101/2024.03.01.582987v1.full.pdf